Either you do not have the newest version of Adobe Flash®, or you have JavaScript disabled.

Please ensure you have these capabilities.

Detection Areas


The incidence of oral cancer is growing at an alarming rate - over 11% in 2007 the United States alone. More deadly than breast cancer, cervical cancer and prostate cancer, oral cancer kills one person, every hour, of every day.

Because the signs and symptoms of oral cancer are often missed by the naked eye alone, Remicalm has put itself at the forefront of oral cancer detection with the development of the Identafi™ 3000 developed using Remicalm's Identafi multispectral optical technology platform. Remicalm's new subsidiary, Trimira™, will be introducing this exciting new technology in the first quarter of 2009.

Trimira's Identafi™ 3000 with Identafi™ technology allows those on the front line of detection to do just that - identify biochemical and morphological changes in cells of the mouth, throat, tongue and tonsils.


According to the National Cancer Institute, in 2008, it is estimated that over 11,000 women in the United States will be diagnosed with cervical cancer and about 3,800 will die. Approximately, 450,000 people are impacted globally.

Worldwide, cervical cancer is the second most common cancer in women (after breast cancer) and is the third leading killer (behind breast and lung cancer). It affects about 16 per 100,000 women per year and causes death in about 9 per 100,000 per year. However, in the United States, thanks in part to traditional screening with the Pap Smear test, cervical cancer is only the 8th most common cancer of women.

The generation of false negative rates and false positive rates from Pap Smears, conservatively, can range upward of 35%. These false indications can, in some part be attributed to slide preparation, processing problems and the inadequacies of sampling. Some experts believe that up to $3 billion a year is spent resolving erroneous screening results generated from Pap Smears.

Remicalm's Identafi™ technology will allow physicians to screen for cervical cancer in-office with immediate results.

Gastrointestinal (bladder, esophagus, colon)

According to the National Cancer Institute, it is estimated that we will witness nearly 69,000 new cases of bladder cancer, and see 14,100 deaths from the disease in 2008.

The numbers are even more alarming for colon and rectal cancer - with an estimated incidence of nearly 150,000 new cases, and 50,000 deaths.

While lesser in number, the cases of esophageal cancer are more deadly - over 16,000 new cases in 2008, and nearly 14,500 deaths.

Cystoscopy, endoscopy and colonoscopy are now the gold standard (respectively) in diagnosing these cancers, but the use of a single white light will not yield the detailed results offered by the Remicalm's Identafi™ technology.


The estimated number of new cases of skin cancer in the US in 2008 is staggering at 1 million. Deaths resulting from non-melanoma cancers will reach over 1000.

In the future, Remicalm's Identafi™ technology will be used to identify areas of concern in the skin.